These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26018128)

  • 1. Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population.
    Evangelista L; Bertagna F; Bertoli M; Stela T; Saladini G; Giubbini R
    Curr Radiopharm; 2016; 9(2):169-77. PubMed ID: 26018128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
    Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
    Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
    Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of FDG-PET in the assessment of survival prognosis in melanoma.
    Pleiss C; Risse JH; Biersack HJ; Bender H
    Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer.
    Vadi SK; Mittal BR; Sood A; Singh G; Bal A; Parihar AS; Bhattacharya A; Basher RK; Kapoor R
    Nucl Med Commun; 2019 Jan; 40(1):63-72. PubMed ID: 30312217
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ulaner GA; Juarez J; Riedl CC; Goldman DA
    J Nucl Med; 2019 Apr; 60(4):472-477. PubMed ID: 30237211
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
    Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
    Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.